Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antigen processing-independent epitopes - Apitope Technology

Drug Profile

Research programme: antigen processing-independent epitopes - Apitope Technology

Alternative Names: API F-VIII; ATX-F8-117; ATX-F8-17; ATX-GD-450; ATX-GD-459; ATX-UV1; ATX-UV2; iATX Factor VIII

Latest Information Update: 15 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apitope Technology
  • Class Peptides
  • Mechanism of Action Immunomodulators; Thyrotropin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Graves' disease; Haemophilia A
  • Research Uveitis

Most Recent Events

  • 15 Mar 2018 Early research is underway for Uveitis (Apitope Technology pipeline, March 2018)
  • 15 Mar 2018 Preclinical development is underway for Autoimmune disorders. Haemophilia A and Graves' disease (Apitope Technology pipeline, March 2018)
  • 15 Mar 2018 Antigen processing-independent epitopes - Apitope Technology is available for licensing as of 15 Mar 2018. https://apitope.com/partnering/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top